arrow
G

Giovanni Caocci

arnas brotzu
H指数:38
被引数:5,370

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study

美洛替尼在鲁索利替尼治疗失败后的临床获益及疗效预测因素:一项合作性真实世界研究

Cancer
IF5.1
2026-05-120
OAAI
Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study

年龄和性别对慢性髓性白血病患者在一线治疗中分子反应的影响:一项意大利CML网络队列研究

2026-04-180
OAAI
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study

意大利阵发性睡眠性血红蛋白尿症患者中拉伏利珠单抗的临床实际应用:来自REACTION观察性研究的证据

2026-01-220
OAAI
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study

阐明慢性髓性白血病患者诊断时外周血白血病干细胞临床作用:FLOWERS前瞻性研究的最终结果

Cancer
IF5.1
2025-10-150
OAAI
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial

健康相关生活质量对慢性髓性白血病患者早期分子应答的预测价值:GIMEMA-SUSTRENIM试验分析

2025-08-270
OA
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

疾病表型显著影响慢性期骨髓纤维化患者停用鲁索利替尼后的结局

2025-03-040
OAAI
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
2025-01-200
OAAI
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management

VEXAS综合征: 更多的是炎症还是造血克隆?诊断,治疗策略和移植管理的病例系列方法

2025-01-170
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or < 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

慢性粒细胞白血病患者在12个月时未达到BCR::ABL1 ≤ 1%(主要分子缓解,MMR)或在24个月时未达到BCR::ABL1 < 0.1%,其生存率显著较差,但并非由于CML相关死亡:一项意大利真实世界观察性研究的数据

BLOOD
IF23.1
2024-11-050
PRE
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50-60 Years: A Campus CML Study

基线特征、治疗选择及早期一线TKI永久停药在50-60岁新诊断慢性髓性白血病患者中的研究:一项Campus CML研究

BLOOD
IF23.1
2024-11-050
PRE
Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

停用一线治疗后慢性粒细胞白血病患者中的无治疗缓解

BLOOD
IF23.1
2024-11-050
PRE